Latigo Biotherapeutics, Inc. (LTGO): who owns it and who trades it
As of Nov 16, 2026, LTGO insiders reported 1 purchase worth $2.5M in the last 12 months. The largest buyer was Foresite Capital Fund VI LP (10% owner), with $2.5M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Latigo Biotherapeutics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, LTGO insiders reported $2.5M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Fund VI LP +5 | 10% owner | Purchase | 140,000 | $18.00 | $2.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Foresite Capital Fund VI LP | 10% owner | $2.5M | – | Aug 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
LTGO short interest
Low short interest. 1.4% of LTGO shares are sold short: about 1 share in 70. Over the last 6 reports the number of shares short went up 600%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 941,434 LTGO shares were sold short, 1.4% of the shares outstanding, up 19.8% from the report before. At the average daily volume of 173,413 shares, buying them all back would take about 5.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 941,434 | 1.42% | +20% | 173,413 | 5.4 |
| Oct 15, 2026 | 785,880 | 1.19% | -6% | 314,757 | 2.5 |
| Sep 30, 2026 | 832,088 | 1.26% | +85% | 519,457 | 1.6 |
| Sep 15, 2026 | 449,962 | 0.68% | +46% | 213,379 | 2.1 |
| Aug 31, 2026 | 308,625 | – | +130% | 179,042 | 1.7 |
| Aug 14, 2026 | 134,468 | – | – | 473,636 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Latigo Biotherapeutics company events
Latigo Biotherapeutics filed 3 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026LeadershipThe Board of Directors of the Company approved the appointment of Todd Smith as the Company’s President and Chief Executive Officer, replacing Nima Farzan in such capacities. Filing
- Sep 3, 2026ResultsReleased financial results. Filing
- Aug 10, 2026AnnouncementThe Company completed its IPO of an aggregate of 19,200,000 shares of common stock at a price to the public of $18.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold LTGO
2 of the 50 well-known investors we track reported holding LTGO in their latest 13F filing. The largest position is Ken Griffin's, worth $1.7M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 101,000 | $1.7M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 83,203 | $1.4M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named LTGO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | 5AM Ventures VI, L.P. | 13G | 7.5% |
| Nov 16, 2026 | 5AM Ventures VI, L.P. | 13G | 7.5% |
| Nov 13, 2026 | Blue Owl Capital Holdings LP | 13G | 5.4% |
| Nov 13, 2026 | Blue Owl Capital Holdings LP | 13G | 5.4% |
| Nov 6, 2026 | AI Biotechnology LLC | 13G/A | 4.8% |
| Nov 6, 2026 | AI Biotechnology LLC | 13G/A | 4.8% |
| Oct 29, 2026 | Westlake BioPartners Fund I, L.P. | 13G | 9.0% |
| Oct 29, 2026 | Westlake BioPartners Fund I, L.P. | 13G | 9.0% |
Questions about Latigo Biotherapeutics, Inc. (LTGO) stock
Are LTGO insiders buying or selling?
In the last 12 months, LTGO insiders reported 1 open-market purchase worth $2.5M and no sales. The latest trade was on Aug 10, 2026. See every trade.
What is the short interest in LTGO?
As of Oct 30, 2026, 941,434 LTGO shares were sold short, 1.4% of the shares outstanding, up 19.8% from the report before. At the average daily volume of 173,413 shares, buying them all back would take about 5.4 trading days (days to cover). See the history.
Which famous investors hold LTGO?
2 of the 50 well-known investors we track reported LTGO in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $1.7M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.